Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
AHK-Cu (Copper Tripeptide-3)
Overview
AHK-Cu is a synthetic copper-binding tripeptide consisting of alanine-histidine-lysine complexed with copper ions. It shares structural and functional similarities with GHK-Cu but contains alanine in place of glycine at the N-terminus.
Mechanism of Action
The peptide is proposed to promote collagen production, angiogenesis, and antioxidant defenses in skin and other tissues.
Research Summary & Key Findings
In vitro studies have shown stimulation of fibroblast proliferation and increased expression of extracellular matrix components. Preclinical dermal models suggest improved wound healing and reduced inflammation with topical application. Clinical evidence is limited to small observational studies in cosmetic formulations, with no published controlled trials in therapeutic indications.
Clinical Status
AHK-Cu (Copper Tripeptide-3) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "AHK-Cu"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "AHK-Cu"
Registered interventional and observational studies, including status and phase.
- PubChem: "AHK-Cu"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Recovery
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis ...
View detailsTB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue re...
View detailsGHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. G...
View detailsDSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood o...
View detailsNo lawful pathway today
AHK-Cu (Copper Tripeptide-3) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.